Markets:

Overview

News

Currencies

International

Treasuries

Viridian Therapeutics, Inc. - Common Stock (NQ:VRDN)

29.27 -0.98 (-3.24%)

Streaming Delayed Price Updated: 3:36 PM EST, Mar 3, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Viridian Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2024

From Viridian Therapeutics, Inc.

Via Business Wire

Here's Why Viridian Therapeutics (VRDN) Stock Is Moving ↗

January 18, 2024

Viridian Therapeutics shares are trading lower by 5.9% Thursday morning. The company announced pricing of an underwritten public offering.

Via Benzinga

Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock

January 17, 2024

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

January 17, 2024

From Viridian Therapeutics, Inc.

Via Business Wire

Analyst Ratings for Viridian Therapeutics ↗

December 04, 2023

Via Benzinga

Where Viridian Therapeutics Stands With Analysts ↗

November 14, 2023

Via Benzinga

Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference

January 08, 2024

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

January 04, 2024

From Viridian Therapeutics, Inc.

Via Business Wire

ZimVie Agrees To Sell Its Spine Business, Joins United States Steel, PGT Innovations And Other Big Stocks Moving Higher On Monday ↗

December 18, 2023

U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 30 points on Monday.

Via Benzinga

Topics Stocks

Analyst Ratings for Viridian Therapeutics ↗

September 13, 2023

Via Benzinga

9 Analysts Have This to Say About Viridian Therapeutics ↗

August 09, 2023

Via Benzinga

Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease

December 18, 2023

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference

November 21, 2023

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 13, 2023

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics to Participate in the Jefferies London Healthcare Conference

November 08, 2023

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces Encore Presentations at the 2023 Annual Meeting of the American Academy of Ophthalmology

November 03, 2023

From Viridian Therapeutics, Inc.

Via Business Wire

Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday ↗

October 30, 2023

U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

Viridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs and Announces $185 Million Private Placement Financing

October 30, 2023

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Subcutaneous Drug Delivery in Thyroid Eye Disease

October 26, 2023

From Viridian Therapeutics, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Tuesday ↗

October 03, 2023

On Tuesday, 647 companies set new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

September 28, 2023

During Thursday's session, 406 companies made new 52-week lows.

Via Benzinga

Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors

September 25, 2023

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces Presentations at Multiple Medical Meetings in September

September 07, 2023

From Viridian Therapeutics, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Tuesday ↗

September 26, 2023

On Tuesday, 386 stocks made new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

September 21, 2023

During the session on Thursday, 461 stocks hit new 52-week lows.

Via Benzinga

Global Payments To Rally Around 17%? Here Are 10 Other Analyst Forecasts For Thursday ↗

August 10, 2023

Keybanc cut the price target for i3 Verticals, Inc. (NASDAQ: IIIV) from $28 to $26. Keybanc analyst Josh Beck maintained an Overweight rating. i3 Verticals shares fell 2.9% to close at $22.76 on...

Via Benzinga

Viridian Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

August 08, 2023

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

August 04, 2023

From Viridian Therapeutics, Inc.

Via Business Wire

2 Growth Stocks Wall Street Analysts Think Can Double in Value ↗

July 19, 2023

Is now a good time to buy these promising healthcare stocks?

Via The Motley Fool

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

July 11, 2023

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.